Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).
Malhotra, J., Malvezzi, M., Negri, E., La Vecchia, C. & Boffetta, P. Risk factors for lung cancer worldwide. Eur. Respir. J. 48, 889–902 (2016).
Zou, K. et al. Etiology of lung cancer: evidence from epidemiologic studies. J. Natl Cancer Cent. 2, 216–225 (2022).
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Personal habits and indoor combustions. IARC Monogr. Eval. Carcinog. Risks Hum. 100, 1–538 (2012).
National Lung Screening Trial Research Team et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395–409 (2011).
Pastorino, U. et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial. Ann. Oncol. 30, 1162–1169 (2019).
de Koning, H. J. et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N. Engl. J. Med. 382, 503–513 (2020).
US Preventive Services Task Force. et al. Screening for lung cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325, 962–970 (2021).
Wolf, A. M. D. et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J. Clin. 74, 50–81 (2024).
Stone, E. & Vachani, A. Tobacco control and tobacco cessation in lung cancer—too little, too late? Semin. Respir. Crit. Care Med. 37, 649–658 (2016).
Marques, P., Piqueras, L. & Sanz, M. J. An updated overview of e-cigarette impact on human health. Respir. Res. 22, 151 (2021).
Obisesan, O. H. et al. Trends in e-cigarette use in adults in the United States, 2016–2018. JAMA Intern. Med. 180, 1394–1398 (2020).
Lindson, N. et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst. Rev. 9, CD015226 (2023).
Balfour, D. J. K. et al. Balancing consideration of the risks and benefits of e-cigarettes. Am. J. Public Health 111, 1661–1672 (2021).
Lang, A. E. et al. England is handing out e-cigarettes: is the ‘swap to stop’ tobacco control scheme harm reduction or harm production? Am. J. Respir. Crit. Care Med. 208, 1024–1025 (2023).
Wills, T. A., Soneji, S. S., Choi, K., Jaspers, I. & Tam, E. K. E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies. Eur. Respir. J. 57, 1901815 (2021).
Gotts, J. E., Jordt, S. E., McConnell, R. & Tarran, R. What are the respiratory effects of e-cigarettes? Brit. Med. J. 366, l5275 (2019).
Pastorino, U. et al. Stopping smoking reduces mortality in low-dose computed tomography screening participants. J. Thorac. Oncol. 11, 693–699 (2016).
Golden, S. E. et al. “I already know that smoking ain’t good for me”: patient and clinician perspectives on lung cancer screening decision-making discussions as a teachable moment. Chest 158, 1250–1259 (2020).
Huerta, T. R., Walker, D. M., Mullen, D., Johnson, T. J. & Ford, E. W. Trends in e-cigarette awareness and perceived harmfulness in the U.S. Am. J. Prev. Med. 52, 339–346 (2017).
Lee, J. A., Kim, S. H. & Cho, H. J. Electronic cigarette use among Korean adults. Int. J. Public Health 61, 151–157 (2016).
Sanford, N. N., Sher, D. J., Xu, X., Aizer, A. A. & Mahal, B. A. Trends in smoking and e-cigarette use among US patients with cancer, 2014–2017. JAMA Oncol. 5, 426–428 (2019).
Heiden, B. T. et al. Prevalence of cigarette and e-cigarette use among U.S. adults eligible for lung cancer screening based on updated USPSTF guidelines. Cancer Epidemiol. 76, 102079 (2022).
Shin, D. W. et al. Lung cancer specialist physicians’ attitudes towards e-cigarettes: a nationwide survey. PLoS ONE 12, e0172568 (2017).
US Preventive Services Task Force. et al. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force Recommendation Statement. JAMA 325, 265–279 (2021).
Soule, E. et al. Electronic cigarette use intensity measurement challenges and regulatory implications. Tob. Control 32, 124–129 (2023).
Cobb, N. K., Brookover, J. & Cobb, C. O. Forensic analysis of online marketing for electronic nicotine delivery systems. Tob. Control 24, 128–131 (2015).
Lee, S., Kimm, H., Yun, J. E. & Jee, S. H. Public health challenges of electronic cigarettes in South Korea. J. Prev. Med. Public Health 44, 235–241 (2011).
Kim, S., Goniewicz, M. L., Yu, S., Kim, B. & Gupta, R. Variations in label information and nicotine levels in electronic cigarette refill liquids in South Korea: regulation challenges. Int. J. Environ. Res. Public Health 12, 4859–4868 (2015).
Tang, M. S. et al. Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice. Proc. Natl Acad. Sci. USA 116, 21727–21731 (2019).
Jensen, R. P., Luo, W., Pankow, J. F., Strongin, R. M. & Peyton, D. H. Hidden formaldehyde in e-cigarette aerosols. N. Engl. J. Med. 372, 392–394 (2015).
Fowles, J., Barreau, T. & Wu, N. Cancer and non-cancer risk concerns from metals in electronic cigarette liquids and aerosols. Int. J. Environ. Res. Public Health 17, 2146 (2020).
Lee, H. W. et al. E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells. Proc. Natl Acad. Sci. USA 115, E1560–E1569 (2018).
Herzog, C. et al. Cigarette smoking and e-cigarette use induce shared DNA methylation changes linked to carcinogenesis. Cancer Res. 84, 1898–1914 (2024).
Velasco, W. V. et al. Comparative effects of combustible cigarette versus electronic cigarette exposures on KRAS mutant lung cancer promotion. Neoplasia 67, 101185 (2025).
Bracken-Clarke, D. et al. Vaping and lung cancer – a review of current data and recommendations. Lung Cancer 153, 11–20 (2021).
Kalkhoran, S. & Glantz, S. A. Modeling the health effects of expanding e-cigarette sales in the United States and United Kingdom: a Monte Carlo analysis. JAMA Intern. Med. 175, 1671–1680 (2015).
Patnode, C. D. et al. Interventions for tobacco cessation in adults, including pregnant persons: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 325, 280–298 (2021).
Lung cancer risk factors. Centers for Disease Control and Prevention https://www.cdc.gov/lung-cancer/risk-factors/index.html (2025).
Tammemagi, M. C. et al. Selection criteria for lung-cancer screening. N. Engl. J. Med. 368, 728–736 (2013).
Cassidy, A. et al. The LLP risk model: an individual risk prediction model for lung cancer. Br. J. Cancer 98, 270–276 (2008).
Tindle, H. A. et al. Lifetime smoking history and risk of lung cancer: results from the Framingham Heart Study. J. Natl Cancer Inst. 110, 1201–1207 (2018).
Meza, R. et al. Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: modeling study for the US Preventive Services Task Force. JAMA 325, 988–997 (2021).
Peto, R. et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. Brit. Med. J. 321, 323–329 (2000).
Rojewski, A. M. et al. Tobacco dependence predicts higher lung cancer and mortality rates and lower rates of smoking cessation in the National Lung Screening Trial. Chest 154, 110–118 (2018).
Tanner, N. T. et al. The association between smoking abstinence and mortality in the National Lung Screening Trial. Am. J. Respir. Crit. Care Med. 193, 534–541 (2016).
Choi, S., Lee, K. & Park, S. M. Combined associations of changes in noncombustible nicotine or tobacco product and combustible cigarette use habits with subsequent short-term cardiovascular disease risk among South Korean men: a nationwide cohort study. Circulation 144, 1528–1538 (2021).
Stephens, W. E. Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke. Tob. Control 27, 10–17 (2018).
Seong, S. C. et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Int. J. Epidemiol. 46, 799–800 (2017).
Seong, S. C. et al. Cohort profile: the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. BMJ Open 7, e016640 (2017).
Shin, D. W., Cho, B. & Guallar, E. Korean National Health Insurance Database. JAMA Intern. Med. 176, 138 (2016).
Son, J. S. et al. Association of blood pressure classification in Korean young adults according to the 2017 American College of Cardiology/American Heart Association Guidelines with subsequent cardiovascular disease events. JAMA 320, 1783–1792 (2018).
Hwangbo, Y. et al. Incidence of diabetes after cancer development: a Korean national cohort study. JAMA Oncol. 4, 1099–1105 (2018).
Reitsma, M. et al. Reexamining rates of decline in lung cancer risk after smoking cessation. A meta-analysis. Ann. Am. Thorac. Soc. 17, 1126–1132 (2020).
Pescatello, L. S., Arena, R., Riebe, D. & Thompson, P. D. ACSM’s Guidelines for Exercise Testing and Prescription (Lippincott Williams & Wilkins, 2014).
Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373–383 (1987).
Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496–509 (1999).
